A detailed history of Thoroughbred Financial Services, LLC transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Thoroughbred Financial Services, LLC holds 52,375 shares of CRDF stock, worth $136,175. This represents 0.01% of its overall portfolio holdings.

Number of Shares
52,375
Holding current value
$136,175
% of portfolio
0.01%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

BUY
$2.22 - $5.89 $116,272 - $308,488
52,375 New
52,375 $116,000

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $113M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Thoroughbred Financial Services, LLC Portfolio

Follow Thoroughbred Financial Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Thoroughbred Financial Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Thoroughbred Financial Services, LLC with notifications on news.